priors.science/reviews/her2-targeted-therapy

HER2 Targeted Therapy

The current evidence on 15 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

15claims tracked
136primary papers reviewed
2 Jun 2026latest evidence review
Weeklyre-scored against new papers
11 Established · 3 Likely · 1 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StablePertuzumab plus trastuzumab: first-line standardMetastatic BreastEstablished95%10
StableTrastuzumab reduces recurrence in early HER2-positive breast cancerEarly Breast CancerEstablished93%10
StableT-DM1 improves outcomes in residual diseaseEarly Breast CancerEstablished93%8
StableT-DXd active in HER2-low breast cancerHER2 LowEstablished93%8
StableT-DXd superior to T-DM1 in metastatic HER2-positive breast cancerMetastatic BreastEstablished93%9
StablePertuzumab improves pathological complete response in the neoadjuvant settingEarly Breast CancerEstablished91%10
StableTrastuzumab improves survival in HER2-positive gastric cancerOther TumoursEstablished91%9
StableCardiotoxicity: HER2-targeted therapy class adverse effectOther TumoursEstablished91%9
StableTucatinib triplet improves survival in HER2-positive breast cancerMetastatic BreastEstablished87%9
StableT-DXd active in HER2-mutant lung cancerOther TumoursEstablished87%9
StableTucatinib reduces central nervous system progression in HER2-positive breast cancerCNS ResistanceEstablished86%9
StableT-DXd has central nervous system activity in HER2-positive breast cancerCNS ResistanceLikely84%9
StableT-DXd active in HER2-amplified colorectal cancerOther TumoursLikely82%9
StablePI3K pathway drives trastuzumab resistanceCNS ResistanceLikely78%8
StableHER2-low is a distinct therapeutic categoryHER2 LowUncertain62%10
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic